These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
61 related articles for article (PubMed ID: 8334790)
1. [Intermittent high-dose vitamin C therapy in patients with HTLV-I-associated myelopathy]. Kataoka A; Imai H; Inayoshi S; Tsuda T Rinsho Shinkeigaku; 1993 Mar; 33(3):282-8. PubMed ID: 8334790 [TBL] [Abstract][Full Text] [Related]
2. Intermittent high-dose vitamin C therapy in patients with HTLV-I associated myelopathy. Kataoka A; Imai H; Inayoshi S; Tsuda T J Neurol Neurosurg Psychiatry; 1993 Nov; 56(11):1213-6. PubMed ID: 8229033 [TBL] [Abstract][Full Text] [Related]
3. Decreased human T lymphotropic virus type I (HTLV-I) provirus load and alteration in T cell phenotype after interferon-alpha therapy for HTLV-I-associated myelopathy/tropical spastic paraparesis. Saito M; Nakagawa M; Kaseda S; Matsuzaki T; Jonosono M; Eiraku N; Kubota R; Takenouchi N; Nagai M; Furukawa Y; Usuku K; Izumo S; Osame M J Infect Dis; 2004 Jan; 189(1):29-40. PubMed ID: 14702150 [TBL] [Abstract][Full Text] [Related]
4. Corticosteroid therapy in TSP/HAM patients: the results from a 10 years open cohort. Croda MG; de Oliveira AC; Vergara MP; Bonasser F; Smid J; Duarte AJ; Casseb J J Neurol Sci; 2008 Jun; 269(1-2):133-7. PubMed ID: 18258264 [TBL] [Abstract][Full Text] [Related]
5. [HTLV-I seronegative idiopathic progressive spastic paraparesis: clinical and neurophysiological study of the sensory features]. Castillo JL; Cea G; Cartier L; Verdugo R Rev Med Chil; 2001 Jul; 129(7):735-41. PubMed ID: 11552441 [TBL] [Abstract][Full Text] [Related]
6. Further studies on HTLV-I associated myelopathy in Argentina. Gonzalez LA; Villa AM; Kohler G; Garcea O; Kremenchutzky M; Caceres F; Sanz OP; Sica RE Medicina (B Aires); 1998; 58(4):411-4. PubMed ID: 9816704 [TBL] [Abstract][Full Text] [Related]
7. [Treatment of HTLV-I-associated myelopathy with alpha-interferon and high-dose of gamma-globulin]. Kuroda Y; Takashima H; Endo C; Neshige R; Kakigi R Rinsho Shinkeigaku; 1990 Jun; 30(6):594-8. PubMed ID: 1699697 [TBL] [Abstract][Full Text] [Related]
8. [Clinical and immunological findings of hepatitis B virus associated spastic paraparesis--a comparison with HAM]. Ayabe M; Imaizumi T; Kikuchi M; Hino H; Shoji H Rinsho Shinkeigaku; 1997 Apr; 37(4):283-6. PubMed ID: 9248335 [TBL] [Abstract][Full Text] [Related]
9. Disulfide-mediated apoptosis of human T-lymphotrophc virus type-I (HTLV-I)-infected cells in patients with HTLV-I-associated myelopathy/tropical spastic paraparesis. Nishiura Y; Nakamura T; Fukushima N; Nakamura H; Ida H; Aramaki T; Eguchi K Antivir Ther; 2009; 14(4):533-42. PubMed ID: 19578238 [TBL] [Abstract][Full Text] [Related]
10. HTLV-1 proviral load in peripheral blood mononuclear cells quantified in 100 HAM/TSP patients: a marker of disease progression. Olindo S; Lézin A; Cabre P; Merle H; Saint-Vil M; Edimonana Kaptue M; Signate A; Césaire R; Smadja D J Neurol Sci; 2005 Oct; 237(1-2):53-9. PubMed ID: 15972218 [TBL] [Abstract][Full Text] [Related]
11. Differentiation of HAM/TSP from patients with multiple sclerosis infected with HTLV-I. Puccioni-Sohler M; Yamano Y; Rios M; Carvalho SM; Vasconcelos CC; Papais-Alvarenga R; Jacobson S Neurology; 2007 Jan; 68(3):206-13. PubMed ID: 17224575 [TBL] [Abstract][Full Text] [Related]